CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).

von Minckwitz G, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, Brunnert K, Gerber B, Vescia S, Wollert J, Kaufmann M

European journal of cancer (Oxford, England : 1990)12 Jun 2006Cited by 32 (Europe PMC)

PMID16765589DOI10.1016/j.ejca.2006.04.006PepBankPUB-16765589

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, first-failure locoregional recurrence occurred in 20 goserelin patients versus 18 CMF patients.
In plain wordsIn premenopausal breast cancer patients, first-failure local recurrence occurred in 20 goserelin patients versus 18 CMF patients.
Peptide
Goserelin
Outcome
Direction not reportedIpsilateral locoregional recurrence
Study
n = 771
Comparator
CMF chemotherapy
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
First-failure ipsilateral locoregional recurrence
18 patients
CMF
First-failure ipsilateral locoregional recurrence
20 patients
goserelin
Source sentences
Summary
The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer.
Summary · context
Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n=378) or goserelin every 28 d for 2 years (n=393).
Report a problemFND-1676558901
02HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, first-failure contralateral breast cancer occurred in 6 goserelin patients versus 7 CMF patients.
In plain wordsIn premenopausal breast cancer patients, cancer in the other breast occurred in 6 goserelin patients versus 7 CMF patients.
Peptide
Goserelin
Outcome
Direction not reportedContralateral breast cancer
Study
n = 771
Comparator
CMF chemotherapy
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
First-failure contralateral breast cancer
7 patients
CMF
First-failure contralateral breast cancer
6 patients
goserelin
Source sentences
Summary
The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer.
Summary · context
Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n=378) or goserelin every 28 d for 2 years (n=393).
Report a problemFND-1676558902
03HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, first-failure distant failure occurred in 24 goserelin patients versus 35 CMF patients.
In plain wordsIn premenopausal breast cancer patients, first-failure distant cancer occurred in 24 goserelin patients versus 35 CMF patients.
Peptide
Goserelin
Outcome
Direction not reportedDistant failure
Study
n = 771
Comparator
CMF chemotherapy
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
First-failure distant failure
35 patients
CMF
First-failure distant failure
24 patients
goserelin
Source sentences
Summary
The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer.
Summary · context
Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n=378) or goserelin every 28 d for 2 years (n=393).
Report a problemFND-1676558903
04HumanRandomized controlled trialSafety outcome
In premenopausal breast cancer patients, death without recurrence occurred in 2 goserelin patients versus 2 CMF patients.
In plain wordsIn premenopausal breast cancer patients, death without recurrence occurred in 2 goserelin patients versus 2 CMF patients.
Peptide
Goserelin
Outcome
Direction not reportedDeath without recurrence
Study
n = 771
Comparator
CMF chemotherapy
Outcome group
Mortality · Cancer
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
First-failure death without recurrence
2 patients
CMF
First-failure death without recurrence
2 patients
goserelin
Source sentences
Summary
The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2).
2 context sentences(design, population, supporting numbers)
Summary · context
Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer.
Summary · context
Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n=378) or goserelin every 28 d for 2 years (n=393).
Report a problemFND-1676558904
05HumanRandomized controlled trialSafety outcome
In premenopausal breast cancer patients, 19 deaths occurred with goserelin versus 23 with CMF.
In plain wordsIn premenopausal breast cancer patients, 19 deaths occurred with goserelin versus 23 with CMF.
Peptide
Goserelin
Outcome
Direction not reportedAll-cause deaths
Study
n = 771
Comparator
CMF chemotherapy
Outcome group
Mortality · Cancer
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Deaths of any cause
42 patients
both arms
Deaths of any cause
23 patients
CMF
Deaths of any cause
19 patients
goserelin
Source sentences
Summary
Forty-two (23 versus 19) deaths of any cause occurred.
3 context sentences(design, population, supporting numbers)
Summary · context
The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2).
Summary · context
Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer.
Summary · context
Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n=378) or goserelin every 28 d for 2 years (n=393).
Report a problemFND-1676558905
06HumanRandomized controlled trialEfficacy outcome
In premenopausal breast cancer patients, the adjusted hazard ratio for goserelin versus CMF was 0.79 (95% CI=0.54-1.14; P=0.19).
In plain wordsIn premenopausal breast cancer patients, the adjusted event hazard did not significantly differ between goserelin and CMF.
Peptide
Goserelin
Outcome
No significant changeFirst-failure hazard
Study
n = 771
Comparator
CMF chemotherapy
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Adjusted hazard ratio, goserelin versus CMF
0.79 ratio
intention-to-treat
95% CI of hazard ratio
0.54 to 1.14 ratio
intention-to-treat
Source sentences
Summary
The estimated adjusted hazard ratio for goserelin versus CMF (intention-to-treat analysis) was 0.79 (95% CI=0.54-1.14; P=0.19).
2 context sentences(design, population, supporting numbers)
Summary · context
Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer.
Summary · context
Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n=378) or goserelin every 28 d for 2 years (n=393).
Report a problemFND-1676558906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.